Efficacy of ravuconazole in treatment of mucosal candidosis in SCID mice

Antimicrobial Agents and Chemotherapy

Volumn 45, Issue 12, 2001, Pages 3433-3436

  Clemons, K V ^a   Stevens, D A ^a  

^a SANTA CLARA VALLEY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; FLUCONAZOLE; RAVUCONAZOLE; UNCLASSIFIED DRUG;

ANIMAL MODEL; ARTICLE; CANDIDA ALBICANS; CANDIDIASIS; COLONY FORMING UNIT; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; MINIMUM INHIBITORY CONCENTRATION; MOUSE; MYCOSIS; NONHUMAN; PRIORITY JOURNAL; SCID MOUSE; THRUSH; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ANIMALS; ANTIFUNGAL AGENTS; CANDIDIASIS, CHRONIC MUCOCUTANEOUS; DIGESTIVE SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; MICE; MICE, SCID; MICROBIAL SENSITIVITY TESTS; THIAZOLES; TRIAZOLES;

EID: 0035191456     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.45.12.3433-3436.2001     Document Type: Article

References (16)

1. Fungal infection in HIV-infected persons
2. Mucosal and disseminated candidiasis in gnotobiotic SCID mice
3. Treatment of orogastrointestinal candidosis in SCID mice with fluconazole alone or in combination with recombinant granulocyte colony stimulating factor or interferon-γ
4. Efficacy of oral amphotericin B in AIDS patients with thrush clinically resistant to fluconazole
5. In vitro activities of BMS-207147 against over 600 contemporary clinical bloodstream isolates of Candida species from the SENTRY Antimicrobial Surveillance Program in North America and Latin America
6. In vitro activity of a new oral triazole, BMS-207147 (ER-30346)
7. BMS-207147
8. Effect of abrogation of natural killer cell activity on the course of candidiasis induced by intraperitoneal administration and gastrointestinal candidiasis in mice with severe combined immunodeficiency
9. Comparison of antifungal activity of amphotericin B deoxycholate suspension with that of amphotericin B cholesteryl sulfate colloidal dispersion
10. Efficacy of ER-30346, a novel oral triazole antifungal agent, in experimental models of aspergillosis, candidiasis, and cryptococcosis
11. In vitro and in vivo antifungal activities of ER-30346, a novel oral triazole with a broad antifungal spectrum
12. Gastrointestinal candidiasis in a murine model of severe combined immunodeficiency syndrome
13. In vitro susceptibilities of Candida dubliniensis isolates tested against the new triazole and echinocandin antifungal agents
14. In vitro susceptibilities of Candida bloodstream isolates to the new triazole antifungal agents BMS-207147, SCH 56592, and voriconazole
15. In vitro antifungal activity of novel azole derivatives with a morpholine ring, UR-9746 and UR-9751, and comparison with fluconazole